Retatrutide Peptide

Retatrutide Peptide
Paub meej:
CAS Nr .: 2381089-83-2
Qhov tsos: Dawb hmoov
MF: C₂₂₁H₃₄₂N₄₆O₆₈
wb :4731
Specifications: Raw hmoov los yog vials daim ntawv
Purity: NLT 99.75%
Solubility: Yooj yim soluble hauv dej
Customization Service: Negotiable; daim ntawv lo, vials loj, thiab mg rau ib lub vial tuaj yeem kho tau. Tab sis peb tsuas yog lees txais kev txiav txim rau kev tshawb fawb.
Xa kev nug
Hauj lwm lawm
Xa kev nug

Retatrutide Peptideyog ib zaug -ib lub lim tiam triple receptor agonist uas ib txhij ua haujlwm GIP, GLP-1, thiab glucagon (GCGR) receptors. Nws lub hom phiaj yog txhawm rau txhim kho peb txoj hauv kev metabolic: GLP-1/GIP sab txhawb nqa cov tshuaj insulin secretion, suppresses qab los noj mov, thiab qeeb plab hnyuv; GCGR sab tuaj yeem ua rau cov roj ntsha oxidation thiab kev siv hluav taws xob ntau ntxiv, yog li ua tiav "ntau lub ntsiab lus tsav" hauv kev poob phaus thiab kev txhim kho metabolic. Lub pharmacokinetic ib nrab-lub neej yog kwv yees li 6 hnub.

Shaanxi Medibridge tau muab peptides rau kev tshawb fawb lub hom phiaj rau ntau lub koom haum tshawb fawb thiab cov tsev kawm qib siab hauv xyoo tas los. Tam sim no, raws li lub chaw tsim tshuaj paus peptide, peb tuaj yeem lav qhov purity ntau dua 99.7% rau peb cov peptides ntev, thiab kev tswj hwm endotoxin thiab cov ntsuas hlau hnyav ua tau raws li cov qauv thoob ntiaj teb.

product-1152-864

 

 

COA

 

product-1265-1787

 

 

Specifications (rau kev tshawb fawb siv nkaus xwb)

 

Daim ntawv

Qauv Order

Specification

Cov hmoov nyoos

1 g

Purity yog NLT 99.75%

Vials

10 vials

3ml / 5ml / 7ml / 15ml vials thiab lwm yam.

 

 

Kev tshawb fawb Sector

Mechanism ntawm Action
Retatrutide peptides ua ib txhij ntawm GIPR, GLP-1R, thiab GCGR. Txoj hauv kev GLP-1 / GIP feem ntau txo qis qab los noj mov, ncua kev ua pa ntawm plab, thiab txhim kho insulin secretion hauv cov xeev hyperglycemic; Kev ua kom nruab nrab ntawm glucagon receptors yuav tsum ua kom muaj roj oxidation thiab siv zog. Nrog lub molecular ib nrab-lub neej ntawm kwv yees li 6 hnub, nws txhawb kev noj tshuaj txhua lub lim tiam. Tag nrho cov qauv tsim kom ua tiav ob qho txiaj ntsig ntawm "kev tswj hwm + kev siv nyiaj ntau ntxiv" kom tau txais cov cim sib sib zog nqus ntawm qhov hnyav thiab kev txhim kho metabolic.
product-1269-712
Theem 2 Cov txiaj ntsig

Hauv cov neeg rog rog yam tsis muaj ntshav qab zib, qhov hnyav poob mus txog qhov siab tshaj plaws ntawm kwv yees li 24% ntawm 48 lub lis piam (siab-dose titration), nrog rau qhov hnyav poob lub hom phiaj ua tiav ntawm Ntau dua lossis sib npaug li 10% thiab ntau dua lossis sib npaug li 15%. Hauv cov tib neeg uas muaj ntshav qab zib hom 2, HbA1c txo qis los ntawm qhov siab tshaj plaws ntawm kwv yees li 2 feem pua ​​​​ntawm cov ntsiab lus ntawm 24 lub lis piam, nrog rau kwv yees li 16-17% poob ntawm 36 lub lis piam. Hais txog daim siab, MRI-PDFF tau pom qhov txo qis ntawm kwv yees li 80% hauv daim siab lipids txheeb ze rau lub hauv paus, nrog ze li 90% ntawm qhov siab - pab pawg koob tshuaj tau txais<5% liver lipids at 48 weeks. Multidimensional outcomes showed good consistency, but long-term maintenance, post-discontinuation changes, and adverse outcomes require further investigation.

product-1312-736
Kev nyab xeeb & Kev kam rau siab

Cov kev phiv tshwm sim feem ntau yog cov tsos mob plab hnyuv (xws li, ntuav, raws plab, cem quav, thiab lwm yam), uas feem ntau mob me me mus rau nruab nrab thiab koob tshuaj - ntsig txog. Ib qho pib qis thiab qeeb qeeb tuaj yeem txhim kho kev ua siab ntev thiab txo qis kev txiav tawm. So lub plawv dhia nce me ntsis los ntawm cov hauv paus ntsiab lus, feem ntau peaking nyob ib ncig ntawm lub lim tiam 24 thiab tom qab ntawd maj mam txo; Kev saib xyuas thaum lub sij hawm titration thiab tu yog pom zoo. Vim nws cov piam thaj -nyob ntawm cov nyhuv insulinotropic, kev pheej hmoo ntawm hypoglycemia raws li kev kho mob monotherapy kuj tsawg; Kev ntsuas tus kheej thiab kev saib xyuas rau kev hloov kho koob tshuaj insulin / sulfonylurea yog tsim nyog thaum siv nrog rau lwm cov tshuaj hypoglycemic. Cov ntaub ntawv kev nyab xeeb tam sim no feem ntau yog raws li Phase II cov ntaub ntawv thiab yuav tsum muaj kev lees paub ntxiv los ntawm qhov loj dua - nplai thiab ntev dua - lub sij hawm ua raws -ups.

product-1267-845
Hepatic Outcomes (MRI{0}}PDFF)
MRI-PDFF tau pom tias muaj qhov txo qis hauv daim siab lipids, nrog qee qhov kev kawm mus txog "siab lipids<5%" threshold at 24–48 weeks. Improved liver lipids were correlated with weight loss, relief of insulin resistance, and reduction in triglycerides. Current analysis did not show a clear increase in drug-induced severe hepatotoxicity signals; however, due to sample size and follow-up time limitations, further histological and long-term clinical outcomes (inflammation, fibrosis, events) are needed for validation. Imaging endpoints are sensitive and easily quantifiable, suitable as early indicators, but do not replace pathological and hard outcomes.
product-1269-712
Synthetic Scheme

Shaanxi Medibridge yog Retatrutide peptide tsum. Peb muab Retatrutide synthesis scheme rau siv los ntawm ntau lub koom haum tshawb fawb los pab txhawb kev sib koom tes.
Hauv qab no yog qib siab, kev tshawb fawb-taw qhia txog hluavtaws hluavtaws rau LY3437943 (ntev, acylated tri-agonist peptide) haum rau txoj kev npaj thiab cov ntaub ntawv. Nws yog txhob txwm ua ntu zus-agnostic thiab tsis rov tsim dua cov ntsiab lus; hloov mus rau koj qhov chaw kuaj SOPs thiab cov kab ke/linker siv.

Modality: Ib zaug xwb - saw peptide (≈35-45 aa) engineered rau balanced GIP/GLP-1/GCGR agonism, nrog N-terminal DPP-4 kuj (xws li, Aib ntawm txoj hauj lwm 2 nyob rau hauv ntau incretin analogs) thiab ib tug ib nrab-lipidation site.

Zuag qhia tag nrho cov tswv yim: Fmoc/tBu khoom-theem peptide synthesis (SPPS) ntawm ib qho amide resin → orthogonal Lys deprotection → ntawm -resin linker/lipidation → N-terminal treatment → global cleavage/deprotection → thim rov qab {analyselyphase → purificationlyphase 3}} khoom.

product-1267-845

 

 

FAQ

 

Q: Puas yog Shaanxi Medibridge tus xa khoom peptide, lossis nws puas tsuas yog muab Retatrutide?

A: Tau kawg, peb yog cov chaw tsim khoom peptide tswj raws li GMP tus qauv. Peb tuaj yeem kho peptides nrog txhua qhov kev txheeb xyuas tau.

Q: Puas yog Retatrutide peb tau yuav siab purity?

A: Yog lawm, peb tuaj yeem muab cov khoom no nrog qhov purity tsawg kawg yog 99.75%. Qee lwm cov tuam txhab me tuaj yeem tswj tau qhov purity ntawm 98.5% thiab 99.1%.

Q: Dab tsi yog qhov khoom muag thiab lub hom phiaj?

A: LY3437943 (qib tshawb fawb) yog ntev - ua peptide ntawm triple receptor agonist chav kawm, rau kev tshawb fawb siv nkaus xwb (RUO). Nws tuaj yeem siv rau hauv kev sim vitro, txoj kev txhim kho, kev tswj xyuas kev tswj xyuas, thiab lwm yam.

Q: Koj puas muaj qhov thib peb - xeem?

A: Tau kawg, txhua pawg tau kuaj los ntawm JANOSHIK lossis Chromate. Peb kuj txhawb cov neeg siv khoom kom muaj qhov thib peb -kev sim ua tiav ntawm txhua pawg ntawm cov khoom lawv yuav.

Q: Koj puas tuaj yeem xa kuv cov khoom tom qab lawv raug ntes los ntawm kev lis kev cai?

A: Tau kawg, qhov mob no yog qhov yooj yim tshaj plaws lav rau peb cov neeg siv khoom. Txawm li cas los xij, peb cov channel logistics zoo heev; peb cov khoom xa tuaj tsuas yog raug kaw peb zaug hauv ib xyoos. Txawm tias cov khoom raug kaw, peb yuav rov teem sijhawm rau lawv.

Q: Kuv yuav khaws cov peptides li cas tom qab kuv tau txais cov khoom?

A: Khaws hauv qhov tsaus ntuj ntawm -20℃txog -80℃; zam rov qab khov-thaw cycles.

Q: Tom qab kuv tau txais lub vial, kuv yuav yaj nws li cas?

A: Reconstitution cov lus pom zoo: maj mam yaj nyob rau hauv sterile buffer (xws li ib tug aqueous system uas muaj ib tug me me npaum li cas ntawm acid / ntsev) ntawm lub hom phiaj concentration; yog tias tsim nyog, siv me me ntawm coagulant (pH / ionic zog / me me ntawm cov organic theem) thiab ua qhov ntsuas me me -; Khaws qhov kub thiab txias thiab txwv lub qhov rais siv thaum siv.

 

Yog tias koj tab tom nrhiav rau siab - zooREtatrutide peptide hmoovcov chaw tsim khoom uas koj tuaj yeem tsim kom muaj sijhawm ntev -, kev sib koom tes ruaj khov, ces Shaanxi Medibridge Biotech Co., Ltd. yuav yog koj tus khub lag luam zoo tshaj plaws. Tsis txhob yig tiv tauj peb ntawm hi@medibridgeapi.com.

 

Cim npe nrov: Tuam Tshoj Retatrutide Peptide manufacturers, lwm tus neeg, Hoobkas

Xa kev nug